PACLITAXEL by Novartis is clinical pharmacology paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. Approved for breast cancer after failure of combination chemotherapy for metastatic disease, relapse within 6 months of adjuvant chemotherapy, combination with cisplatin. First approved in 2007.
Drug data last refreshed 10h ago
CLINICAL PHARMACOLOGY Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that…
Worked on PACLITAXEL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel